• We propose to bring to market a ground-breaking treatment to retard the onset of or prevent Alzheimer’s disease (AD). • The concept is based on original new observations that have emerged from our studies showing that there is age-related damage to the tiny capillary blood vessels (called the blood brain barrier or BBB), which supply the brain, and that the major genetic and non-genetic risk factors for AD greatly worsen this damage. BBB damage is a major pathology in symptomatic and pre-symptomatic AD. • BBB leakage is found to occur in middle age in humans and pre-clinical models. This BBB damage primarily affects the brain in the hippocampus, which is important for memory, and is particularly affected in AD. • These observations are consistent with the strongly supported concept that AD is a disease of the capillary blood supply to the brain, particularly in its early stages. • Our studies identify a fundamental mechanism underlying this damage, which can be targeted and healed with a known drug that is licensed for a completely different purpose. • The value in the concept both therapeutically and financially can be developed by targeting the known drug for an Orphan indication involving damage to the BBB, which would provide exclusivity for a period of time. • In parallel we will develop a better targeted new drug(s). • Additionally we will develop biomarkers for BBB damage that can be used to indicate the use of our drug through the prediction of AD risk, and monitor its efficacy. • We are seeking foresighted investors with an interest in the early-stage development of high-impact biopharmaceutical products in order to advance our concept. Funds secured will be used to advance the company’s ~£6.0-7.0 million Discovery and Development, and Preclinical program for AD risk modification, with additional ~£3.0-4.0 million funding for phase 1 human studies. • There are caveats to the Company valuation because of the existence of a known drug that can heal the BBB. - Repurposing might be challenging as the acute clinical trials have shown no improvement in cognition with the known drug, so that a longer expensive, trial is needed, but the length of this trial may well be mitigated by the use of our biomarkers. - The valuation is also complicated by the commercial impact of generic pricing following expiration of the know drugs patents which may limit pricing and reduce the attractiveness to a large Pharma partner. • Importantly, our strategy is anticipated to provide a preventative treatment for this devastating disease for which there is no treatment, and where there have been multiple drug development failures. This, irrespective of remuneration would have a huge impact by improving human suffering. • We suggest the conservative valuation of $US 20-30 million upfront at the end of the pre-clinical stage and $US 60-90 million deal total deal value. • This would give a more than 5 to 8 fold return on investment of £11.0 million. • However, the anticipated “frenzy” of demand that might well be generated by rapidly bringing to market a preventative drug treatment strategy for AD very likely trigger very substantial sales, with greatly enhanced Company valuation.,• We propose to bring to market a ground-breaking treatment to retard the onset of or prevent Alzheimer’s disease (AD). • The concept is based on original new observations that have emerged from our studies showing that there is age-related damage to the tiny capillary blood vessels (called the blood brain barrier or BBB), which supply the brain, and that the major genetic and non-genetic risk factors for AD greatly worsen this damage. BBB damage is a major pathology in symptomatic and pre-symptomatic AD. • BBB leakage is found to occur in middle age in humans and pre-clinical models. This BBB damage primarily affects the brain in the hippocampus, which is important for memory, and is particularly affected in AD. • These observations are consistent with the strongly supported concept that AD is a disease of the capillary blood supply to the brain, particularly in its early stages. • Our studies identify a fundamental mechanism underlying this damage, which can be targeted and healed with a known drug that is licensed for a completely different purpose. • The value in the concept both therapeutically and financially can be developed by targeting the known drug for an Orphan indication involving damage to the BBB, which would provide exclusivity for a period of time. • In parallel we will develop a better targeted new drug(s). • Additionally we will develop biomarkers for BBB damage that can be used to indicate the use of our drug through the prediction of AD risk, and monitor its efficacy. • We are seeking foresighted investors with an interest in the early-stage development of high-impact biopharmaceutical products in order to advance our concept. Funds secured will be used to advance the company’s ~£6.0-7.0 million Discovery and Development, and Preclinical program for AD risk modification, with additional ~£3.0-4.0 million funding for phase 1 human studies. • There are caveats to the Company valuation because of the existence of a known drug that can heal the BBB. - Repurposing might be challenging as the acute clinical trials have shown no improvement in cognition with the known drug, so that a longer expensive, trial is needed, but the length of this trial may well be mitigated by the use of our biomarkers. - The valuation is also complicated by the commercial impact of generic pricing following expiration of the know drugs patents which may limit pricing and reduce the attractiveness to a large Pharma partner. • Importantly, our strategy is anticipated to provide a preventative treatment for this devastating disease for which there is no treatment, and where there have been multiple drug development failures. This, irrespective of remuneration would have a huge impact by improving human suffering. • We suggest the conservative valuation of $US 20-30 million upfront at the end of the pre-clinical stage and $US 60-90 million deal total deal value. • This would give a more than 5 to 8 fold return on investment of £11.0 million. • However, the anticipated “frenzy” of demand that might well be generated by rapidly bringing to market a preventative drug treatment strategy for AD very likely trigger very substantial sales, with greatly enhanced Company valuation.